ADMA Biologics Inc
NASDAQ:ADMA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.7
22.62
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ADMA stock under the Base Case scenario is 8.63 USD. Compared to the current market price of 21.18 USD, ADMA Biologics Inc is Overvalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ADMA Biologics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ADMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ADMA Biologics Inc
Balance Sheet Decomposition
ADMA Biologics Inc
Current Assets | 318.2m |
Cash & Short-Term Investments | 86.7m |
Receivables | 50.1m |
Other Current Assets | 181.3m |
Non-Current Assets | 72.4m |
PP&E | 62.6m |
Intangibles | 4m |
Other Non-Current Assets | 5.8m |
Current Liabilities | 44.9m |
Accounts Payable | 16m |
Accrued Liabilities | 25.4m |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 113.8m |
Long-Term Debt | 101.3m |
Other Non-Current Liabilities | 12.5m |
Earnings Waterfall
ADMA Biologics Inc
Revenue
|
382.8m
USD
|
Cost of Revenue
|
-195.5m
USD
|
Gross Profit
|
187.3m
USD
|
Operating Expenses
|
-98.6m
USD
|
Operating Income
|
88.7m
USD
|
Other Expenses
|
-20.6m
USD
|
Net Income
|
68.1m
USD
|
Free Cash Flow Analysis
ADMA Biologics Inc
USD | |
Free Cash Flow | USD |
In its third quarter, ADMA Biologics achieved outstanding results, with revenues soaring 78% year-over-year to $119.8 million. Adjusted EBITDA surged 256% to $45.4 million, and net income skyrocketed 1,300% to $35.9 million. The company has raised its revenue guidance to over $415 million for 2024 and $465 million for 2025, expecting adjusted EBITDA to exceed $160 million and $215 million, respectively. The demand for ASCENIV reinforces expectations for strong growth, with potential for it to reach $1 billion in annual revenue. Strategic initiatives like plasma donor retention programs and enhanced production efficiencies are expected to bolster earnings further.
What is Earnings Call?
ADMA Profitability Score
Profitability Due Diligence
ADMA Biologics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
ADMA Biologics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
ADMA Solvency Score
Solvency Due Diligence
ADMA Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
ADMA Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADMA Price Targets Summary
ADMA Biologics Inc
According to Wall Street analysts, the average 1-year price target for ADMA is 23.91 USD with a low forecast of 17.4 USD and a high forecast of 27.3 USD.
Dividends
Current shareholder yield for ADMA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ADMA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 527 full-time employees. The company went IPO on 2013-10-17. The firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.
Contact
IPO
Employees
Officers
The intrinsic value of one ADMA stock under the Base Case scenario is 8.63 USD.
Compared to the current market price of 21.18 USD, ADMA Biologics Inc is Overvalued by 59%.